Five stocks witnessing long built-up
Five stocks witnessing long built-up

Five stocks witnessing long built-up

Ganesh Pawar Article rating: 4.0

The market opened in green on July 27, 2021, overall volumes in futures & options currently stand at 4,28,58,792 contracts with a turnover of Rs. 36,04,114.35 crore.

Five stocks witnessing short built-up
Five stocks witnessing short built-up

Five stocks witnessing short built-up

Ganesh Pawar Article rating: 2.9

The market opened in green on July 27, 2021, overall volumes in futures & options currently stand at 4,28,58,792 contracts with a turnover of Rs. 36,04,114.35 crore.

KPIT Technologies reports strong performance in Q1FY22; share gains on Tuesday
KPIT Technologies reports strong performance in Q1FY22; share gains on Tuesday

KPIT Technologies reports strong performance in Q1FY22; share gains on Tuesday

The stock has delighted investors by delivering gains of 347.35 per cent in the last one year & 108.03 per cent in 2021, so far.

Shreya Chaware Article rating: 3.4

KPIT Technologies, an Indian multinational corporation, announced its quarterly results for Q1FY22. During the year, the company has also entered T25 engagements across geographies.

Jindal Stainless rallies 5 per cent on posting strong Q1 results; announces Rs 2,150 crore expansion plan
Jindal Stainless rallies 5 per cent on posting strong Q1 results; announces Rs 2,150 crore expansion plan

Jindal Stainless rallies 5 per cent on posting strong Q1 results; announces Rs 2,150 crore expansion plan

The estimated Capex of this brownfield expansion is Rs 2,150 crore. The three-pronged expansion plan envelopes the expansion of melting capacity and commensurate strengthening of forward as well as backward linkages.

Armaan Madhani Article rating: 3.0

The company accelerated its deleveraging strategy during the quarter and narrowed long-term external debt (excluding group company JSHL’s debt) by Rs 210 crore.

Biocon Biologics partners with Adagio Therapeutics to advance antibody for COVID-19 prevention & treatment
Biocon Biologics partners with Adagio Therapeutics to advance antibody for COVID-19 prevention & treatment

Biocon Biologics partners with Adagio Therapeutics to advance antibody for COVID-19 prevention & treatment

ADG20 is a novel monoclonal antibody, targeting the spike protein of related Coronaviruses and SARS-CoV-2. It is currently in global clinical development by Adagio as a single agent for both prevention and treatment of Coronavirus.

Armaan Madhani Article rating: 4.0

The fully-integrated biosimilars company, Biocon Biologics Ltd, a subsidiary of Biocon Ltd reported that US-based Adagio Therapeutics has granted them an exclusive licence to manufacture and commercialise, broadly neutralising antibody treatment based on ADG20 for India as well as select emerging markets. 

RSS
First22752276227722782280228222832284Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR